VetDC Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $700K
Latest Deal Amount
  • Investors
  • 17

VetDC General Information

Description

Developer of cancer treatment drugs intended to treat lymphoma in dogs. The company's drugs identify and evaluate novel anti-cancer therapies and advance them rapidly in pets, enabling veterinary doctors to cure cancer in canine companions.

Contact Information

Website
www.vet-dc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Other Pharmaceuticals and Biotechnology
Primary Office
  • 320 East Vine Drive
  • Suite 218
  • Fort Collins, CO 80524
  • United States
+1 (877) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

VetDC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 30-Sep-2016 $700K 00.000 0000 Completed Generating Revenue
9. Later Stage VC (Series B) 31-Mar-2015 00.00 00.000 000.00 Completed Generating Revenue
8. Early Stage VC (Series A2) 10-Nov-2014 00.000 00.000 0000 Completed Generating Revenue
7. Grant 20-Dec-2013 00000 00.000 Completed Generating Revenue
6. Early Stage VC (Series A2) 01-Dec-2013 00.000 00.000 00.00 Completed Generating Revenue
5. Early Stage VC (Series A2) 01-Apr-2013 00.000 00.000 00.000 Completed Generating Revenue
4. Accelerator/Incubator 00.00 Completed Generating Revenue
3. Early Stage VC (Series A2) 28-Nov-2012 00.000 00.00 00.000 Completed Generating Revenue
2. Early Stage VC (Series A1) 01-Nov-2012 $40K $40K 00000 Completed Generating Revenue
1. Grant 12-Sep-2012 $7K Completed Generating Revenue
To view VetDC’s complete valuation and funding history, request access »

VetDC Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A2 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A1 600,000 $0.001000 $0.07 $1.5 22x $0.07 4.83%
To view VetDC’s complete cap table history, request access »

VetDC Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer treatment drugs intended to treat lymphoma in dogs. The company's drugs identify and evaluate novel
Drug Discovery
Fort Collins, CO
4 As of 2018
00.000
000 0000-00-00
0000000000 0 00.000

000000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
000000000000000
Parsippany, NJ
00000 As of 0000
00.000
00000000000 00.000

0000000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
000000000 (000)
San Francisco, CA
000 As of 0000
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

VetDC Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zoetis Corporation Parsippany, NJ 00000 00.000 00000000000 00.000
0000000 Formerly VC-backed San Francisco, CA 000 000.00 000000&0 000.00
0000000 Formerly VC-backed Miyazaki, Japan 00 00.000 000000&0 00.000
You’re viewing 3 of 3 competitors. Get the full list »

VetDC Executive Team (6)

Name Title Board Seat Contact Info
Steven Roy Chief Executive Officer, President and Board Member
Terry Opgenorth Ph.D Co-Founder, Chief Scientific Officer and Board Observer
Douglas Thamm Head, Clinical Development
Cathy Gust Ph.D Head, Operations
Douglas Johnson Ph.D Senior Director, Pharmaceutical Operations
You’re viewing 5 of 6 executive team members. Get the full list »

VetDC Board Members (7)

Name Representing Role Since
John Adams Sr. Self Board Member & Advisor 000 0000
Mark Lupa Ph.D Self Board Member 000 0000
Richard Duke Ph.D Self Board Observer 000 0000
Richard Fort Ph.D Self Board Member 000 0000
Steve Warnecke Ph.D Self Chairman 000 0000
You’re viewing 5 of 7 board members. Get the full list »

VetDC Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VetDC Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DuWayne Peterson Angel (individual) Minority 000 0000 000000 0
Gregory Tucker Angel (individual) Minority 000 0000 000000 0
Ken Spratlin Angel (individual) Minority 000 0000 000000 0
Paul Neilson Angel (individual) Minority 000 0000 000000 0
Peter Adams Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

VetDC Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 14-Aug-2013 000000000000000000 Pharmaceuticals
To view VetDC’s complete acquisitions history, request access »